



Poly Medicure Ltd.

POLYMED
Medical Devices

Works : Plot No. 104-105, Sector-59, HSIDC Industrial Area, Ballabgarh, Faridabad-121004, INDIA
Phone : +91-129-2307000, 4287000 Fax : +91-129-2307007, 2309102
E-mail : info@polymedicure.com, Website : www.polymedicure.com

Ref: PML/SEC/2011-12/349

Date: 30th January, 2012

The Manager (Listing)
National Stock Exchange of India Limited
Exchange Plaza,
Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051.

Sub: Outcome of the Board Meeting

Dear Sir/Madam,

With reference to the Captioned subject, please find enclosed herewith Un-Audited Financial Results for the quarter ended 31st December, 2011 and respective Limited Review for that period for your record please.

Kindly take a note of the same for your further needful and oblige us.

Thanking You,

Yours Faithfully

For Poly Medicure Limited


Sonia Singh
Company Secretary

DOOGAR & ASSOCIATES

Chartered Accountants

Limited Review Report

The Board of Directors

Poly Medicure Limited
1st Floor, 12, Sant Nagar,
East of Kailash,
New Delhi – 110 065.

Dear Sirs,

1. We have reviewed the accompanying statement of unaudited financial results of M/s Poly Medicure Limited (the 'Company') for the quarter ended 31st December, 2011 except for the disclosures regarding "Promoters' shareholding" and "Promoters and promoters group shareholding" which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this financial statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, "Engagements to Review Financial Statements" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Doogar & Associates**
Chartered Accountants
(Regn. No. 000561N)



(M. S. Agarwal)
Partner

Mem. No.: 086580

Place: New Delhi

Date: 30.01.2012

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2011

Sr. no.	Particulars	Quarter Ended			Nine Months Ended		(₹ In lacs)
		31.12.2011	30.09.2011	31.12.2010	31.12.2011	31.12.2010	31.03.2011
		(Unaudited)			(Unaudited)		(Audited)
1	Gross Sales	5,509.23	5,014.44	4,178.98	15,071.31	12,250.57	16,765.13
	Less-Excise Duty	79.34	57.02	44.44	177.77	124.65	170.29
	(a) Net Sales	5,429.89	4,957.42	4,134.54	14,893.54	12,125.92	16,594.84
	(b) Other Operating Income	88.15	92.14	40.43	283.72	219.69	371.91
	Total Income	5,518.04	5,049.57	4,174.97	15,177.26	12,345.61	16,966.75
2	Expenditure						
	a. (Increase)/Decrease in stock in trade and work in progress	(56.49)	(119.43)	(6.32)	(225.80)	31.61	98.61
	b. Consumption of Raw materials	1,931.29	1,788.48	1,668.57	5,371.21	4,616.56	6,244.17
	c. Purchase of traded goods	170.73	211.15	21.33	482.92	72.19	174.77
	d. Employee Cost	893.73	852.38	666.58	2,525.00	2,006.85	2,659.71
	e. Depreciation	255.99	239.30	231.68	727.05	626.66	858.78
	f. Other Expenditure	1,581.34	1,249.87	960.19	3,846.03	3,063.85	4,132.07
	g. Total	4,776.59	4,221.76	3,542.03	12,726.41	10,417.72	14,168.11
3	Profit from Operations before Other Income, Interest & Exceptional Items	741.45	827.81	632.94	2,450.85	1,927.89	2,798.63
4	Other Income	11.50	9.62	8.26	26.98	21.61	39.31
5	Profit before Interest & Exceptional items	752.95	837.43	641.20	2,477.83	1,949.51	2,837.94
6	Interest & Finance Charges	125.55	133.35	116.00	379.98	332.10	444.10
7	Profit after Interest but before Exceptional Items	627.40	704.07	525.20	2,097.85	1,617.41	2,393.85
8	Exceptional items	-	-	-	-	-	-
9	Profit/(Loss) from Ordinary activities before Tax	627.40	704.07	525.20	2,097.85	1,617.41	2,393.85
10	Tax Expenses	226.45	227.38	41.75	686.97	160.75	224.83
11	Net Profit/(Loss) from Ordinary Activities after Tax	400.95	476.69	483.45	1,410.88	1,456.66	2,169.02
12	Extraordinary Item	-	-	-	-	-	-
13	Net Profit/(Loss) for the period	400.95	476.69	483.45	1,410.88	1,456.66	2,169.02
14	Paid up Equity Share Capital (Face value ₹ 10/- per Share)	1,101.25	1,101.25	1,101.25	1,101.25	1,101.25	1,101.25
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						6,676.49
16	Earning Per Share-Basic and Diluted (₹) - Not annualised	3.64	4.33	4.39	12.81	13.23	19.70
17	Public shareholding						
	-No. of Shares	56,49,781	56,49,781	56,91,688	56,49,781	56,91,688	56,49,781
	-Percentage of Shareholding	51.30%	51.30%	51.68%	51.30%	51.68%	51.30%
18	Promoters and promoters group shareholding						
	a) Pledged / Encumbered						
	- Number of shares	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of shares	53,62,719	53,62,719	53,20,812	53,62,719	53,20,812	53,62,719
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the Company	48.70%	48.70%	48.32%	48.70%	48.32%	48.70%

Notes

- The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- There were no unresolved investors' complaints as on 30th September 2011. No complaint was received during the current quarter. There was no pending unresolved complaint as on 31st Dec 2011.
- In view of option allowed by the Ministry of Corporate Affairs vide its notification dated 29th December 2011 on AS 11, the exchange differences arising on reporting of long term foreign currency monetary items at rates different from those at which they were initially recorded have been accumulated in a "Foreign Currency Monetary Items Translation Difference Account" to be amortised over the balance period of such long term assets or liabilities. Pursuant to such adoption, a sum of ₹ 201.49 lacs is remained to be amortised over the balance period of such assets or liabilities, out of which a sum of ₹ 132.19 lacs has already been recovered, if reinstatement of such long term foreign currency monetary items are done on the basis of foreign exchange rate prevailing today i.e. on 30th January, 2012.
- Other expenditure for the quarter and nine months ended 31st December 2011 includes ₹ 425.79 lacs and ₹ 469.81 lacs respectively towards net foreign exchange loss.
- The shares of the company have been admitted for dealing on National Stock Exchange "NSE" with effect from 07th December 2011
- The above results have been reviewed by the Statutory Auditors, Audit Committee and approved by the Board of Directors in their meeting held on 30th Jan, 2012.
- The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

Place : New Delhi
Date : 30.01.2012



By order of the Board
Himanshu Baid
Himanshu Baid
Managing Director